Clinical Development Pipeline
PALI-2108 is a differentiated, once-daily oral PDE4 inhibitor prodrug in Phase 2 development for ulcerative colitis and Crohn’s disease.
Program
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Milestones
PALI-2108
Ulcerative Colitis (UC)
- Global randomized, placebo-controlled
- Moderate to severe UC
- 204 patients
- 12-week induction
- Primary endpoint: Clinical Remission
IND Cleared
Phase 2 enrollment expected H2 2026
Primary readout H2 2027 (12-week)
PALI-2108
Crohn's Disease (CD)
- Open-label study
- Moderate to severe CD
- 50–60 patients
- Study design being finalized
Phase 2 planned
Enrollment anticipated 2026/27
Primary readout expected 2027/28
Pipeline Expansion Opportunities
Fibrostenotic Crohn’s Disease (FSCD)
Phase 1 completed
Positive Phase 1b data in FSCD supports further exploration in this high unmet need population.
Other Immune-Mediated Diseases
Future expansion
Future opportunities across inflammatory and fibrotic diseases leveraging validated PDE4 biology and Palisade’s targeted prodrug.